Sara Raponi

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients.

Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients.

Journal: British journal of haematology
Published: March 29, 2023

Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.

Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.

Journal: British journal of haematology
Published: September 04, 2022

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.

Journal: Cancers
Published: December 10, 2021

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.

Journal: Blood
Published: April 02, 2021

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.

Journal: Haematologica
Published: October 05, 2020

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia.

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia.

Journal: Haematologica
Published: June 18, 2020

Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL).

Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL).

Journal: Leukemia
Published: February 17, 2020

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).

Journal: Haematologica
Published: January 30, 2020

Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.

Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.

Journal: British journal of haematology
Published: September 02, 2019

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

Journal: Frontiers in oncology
Published: March 27, 2019

Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.

Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.

Journal: British journal of haematology
Published: May 31, 2018

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Journal: British journal of haematology
Published: May 23, 2018
Showing 1-12 of 29

Last Updated: 09/26/2026